06.03.2018
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Internationalization of Business Activities - BRAIN AG establishes US subsidiary to strengthen business development in North America
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Strategic Company Decision
B.R.A.I.N. Biotechnology Research And Information Network AG:
Internationalization of Business Activities - BRAIN AG establishes US
subsidiary to strengthen business development in North America
06.03.2018 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Internationalization of Business Activities
BRAIN AG establishes US subsidiary to strengthen business development in
North America
* More effective addressing of attractive target markets and improved
customer relationships
* Synergies with US presence of subsidiary AnalytiCon Discovery LLC
Zwingenberg
March 6, 2018
In order to address the North American markets of importance for the BRAIN
Group more effectively, the German bio-economy pioneer BRAIN AG,
headquartered in Zwingenberg, has founded the US subsidiary B.R.A.I.N.
Biotechnology Research and Information Network US LLC (short: BRAIN LLC).
This strategic step is intended to accelerate the internationalization of
BRAIN's business operations, improve customer relations and intensify the
Group's business development with a US presence. In addition, the company
plans to expand its links with international research co-operations, in
which BRAIN is already involved to some extent successfully. The newly
founded BRAIN LLC is based in Rockville, Maryland, near Washington DC. After
the company was founded and recorded in the previous month it now starts
operations. BRAIN AG holds 100% of the shares in BRAIN LLC.
Nearby BRAIN LLC is the US representative office of the BRAIN subsidiary
Analyticon Discovery GmbH, Potsdam. BRAIN Group expects synergies and faster
market access for its own product and process developments through the
co-operation of the two US branches.
BRAIN AG has taken a series of strategic measures since the beginning of the
financial year 2017/18 with the aim of expanding business development and
market access for BRAIN innovations. Dr. Jürgen Eck, CEO of BRAIN AG,
commented: "The establishment of BRAIN LLC in the US state of Maryland is
aimed at driving forward the internationalization of our business
development. In order to be able to market our product and process
innovations in the important future market of bio-economics more effectively
internationally in the future, direct market access is of great importance.
Our M&A strategy and the preparation of product-specific spin-offs to
strengthen our product-driven business segment BioIndustrial also contribute
to this."
BRAIN AG and Analyticon Discovery GmbH are already partners in important
product developments of BRAIN Group such as the DOLCE program for the
development of biological sugar substitutes and sweetener enhancers. Several
US companies have already been acquired as development partners in this
program.
BRAIN and Analyticon Discovery also work closely together in other
development programs based on naturally derived active ingredients for
different target industries. In addition to the targeted reduction of sugar
in the food industry, this also applies to the reduction of salt and fat in
foods and beverages as well as natural substances that prevent harmful germs
and spoilage of food products. This includes, for example, the
PerillicActive development program for natural active ingredients based on
fermented orange oil.
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN
DE0005203947 / WKN 520394) is one of Europe's leading technology companies
in the field of industrial biotechnology, the core discipline of Bioeconomy.
As such, BRAIN identifies previously untapped, efficient enzymes, microbial
producer organisms or natural substances from complex biological systems
that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in
the chemistry, the cosmetics and the food industries. BRAIN's business model
is based on two pillars - BioScience and BioIndustrial. The BioScience
comprises its frequently exclusive collaboration business with industrial
partners. BioIndustrial comprises the development and commercialization of
BRAIN's own products and active product components. Further information is
available at www.brain-biotech.de/en.
BRAIN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.de
Contact Media
Thomas Deichmann
Head of Public Relations
Tel.: +49-(0)-6251-9331-72
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]
Contact Investor Relations
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-(0)-6251-9331-16
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]
Follow us on Twitter
https://twitter.com/BRAINbiotech
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN group of companies. Such factors include, but are not
limited to, changes in the general economic and competitive environment,
risks associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.
---------------------------------------------------------------------------
06.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
660439 06.03.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN